Freedom of Information request on the PAR and therapeutic indications for the glycopyrronium products by Morningside Healthcare (FOI 21/1317)
Published 31 May 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-20-december-2021/freedom-of-information-request-on-the-par-and-therapeutic-indications-for-the-glycopyrronium-products-by-morningside-healthcare-foi-211317
FOI 21/1317
24th December 2021
Dear,
Thank you for your email.
The PAR for the glycopyrronium products by Morningside Healthcare is linked below:
https://mhraproducts4853.blob.core.windows.net/docs/839e8c2eff41dd79a4c179b57e4b9430985d9af5
The following PAR is published for the requested therapeutic indications:
https://mhraproducts4853.blob.core.windows.net/docs/dfb575da354224d5eabd2a7487025e026221cb9c
Kind regards,
MHRA Customer Service Centre
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU
Telephone 020 3080 6000